Vivaldi Biosciences AG

Founded

2014

Staff

3

Organization type

RDM biotech/pharma

Region

Vienna

Cluster

LISAvienna

Focus

human health

Vivaldi Biosciences is developing its DeltaFLU influenza vaccine to provide broad cross-protection and superior efficacy in the prophylaxis of seasonal and pandemic influenza. DeltaFLU is composed of influenza vaccine strains genetically modified by deletion of the gene for nonstructural protein 1.

R&D:Administered as a nasal spray, DeltaFLU generates a first line of defense at the point of entry of circulating viruses. In clinical trials, DeltaFLU has been shown to induce antibodies in the nasal mucosa that cross-neutralize influenza strains of different subtypes. DeltaFLU strains are replication-deficient in animals and humans and are not shed by the recipient, providing significant safety advantages.